Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2

Chantal B. F. Vogels(Yale University), Mallery I. Breban(Yale University), Isabel M. Ott(Yale University), Tara Alpert(Yale University), Mary E. Petrone(Yale University), Anne E. Watkins(Yale University), Chaney C. Kalinich(Yale University), Rebecca Earnest(Yale University), Jessica E. Rothman(Yale University), Jaqueline Góes de Jesus(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Ingra Morales Claro(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Giulia Magalhães Ferreira(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Myuki Alfaia Esashika Crispim(Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas), Brazil-UK CADDE Genomic Network(University of KwaZulu-Natal), Lavanya Singh(University of KwaZulu-Natal), Houriiyah Tegally(University of KwaZulu-Natal), Ugochukwu J. Anyaneji(University of Bern), Network for Genomic Surveillance in South Africa(Tempus Labs (United States)), Emma B. Hodcroft(University of Bern), Christopher E. Mason(Tempus Labs (United States)), Gaurav Khullar(Tempus Labs (United States)), Jessica Metti(Tempus Labs (United States)), Joel T. Dudley(Tempus Labs (United States)), Matthew MacKay(Yale University), Megan Nash(Yale University), Jianhui Wang(Yale University), Chen Liu(Murphy Oil Corporation (United States)), Pei Hui(Murphy Oil Corporation (United States)), Steven Murphy(Murphy Oil Corporation (United States)), Caleb Neal(Murphy Oil Corporation (United States)), Éva László(United States Department of State), Marie L. Landry(United States Department of State), Anthony Muyombwe(United States Department of State), Randy Downing(United States Department of State), Jafar Razeq(United States Department of State), Túlio de Oliveira(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Nuno R. Faria(SIB Swiss Institute of Bioinformatics), Éster Cerdeira Sabino(Yale University), Richard A. Neher(SIB Swiss Institute of Bioinformatics), Joseph Fauver(Yale University), Nathan D. Grubaugh(Yale University)
PLoS Biology
May 7, 2021
Cited by 233Open Access
Full Text

Abstract

With the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants that may increase transmissibility and/or cause escape from immune responses, there is an urgent need for the targeted surveillance of circulating lineages. It was found that the B.1.1.7 (also 501Y.V1) variant, first detected in the United Kingdom, could be serendipitously detected by the Thermo Fisher TaqPath COVID-19 PCR assay because a key deletion in these viruses, spike Δ69-70, would cause a "spike gene target failure" (SGTF) result. However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern (VOC) that lack spike Δ69-70, such as B.1.351 (also 501Y.V2), detected in South Africa, and P.1 (also 501Y.V3), recently detected in Brazil. We identified a deletion in the ORF1a gene (ORF1a Δ3675-3677) in all 3 variants, which has not yet been widely detected in other SARS-CoV-2 lineages. Using ORF1a Δ3675-3677 as the primary target and spike Δ69-70 to differentiate, we designed and validated an open-source PCR assay to detect SARS-CoV-2 VOC. Our assay can be rapidly deployed in laboratories around the world to enhance surveillance for the local emergence and spread of B.1.1.7, B.1.351, and P.1.


Related Papers

No related papers found

Powered by citation graph analysis